 NeuBase Therapeutics, Inc. Nasdaq: NBSE NeuBase or the Company, a biotechnology company developing next-generation antisense oligonucleotide ASO therapies to address genetic diseases, today announced positive preclinical data from its pharmacokinetics studies in non-human primates NHPs and in vitro pharmacodynamics data in patient-derived cell lines. NeuBase believes these data validate the key advantages of the proprietary NeuBase peptide-nucleic acid PNA antisense oligonucleotide PATrOLTM platform and support the Companys decision to advance the development of its Huntingtons disease HD and myotonic dystrophy type 1 DM1 programs, as well as the potential expansion of its therapeutic pipeline into other indications. 